July 18, 2012 -- Gregory S Burton, the new US Consul General in Northern Ireland, visited Almac’s headquarters in Craigavon today for a first hand overview of the Company’s latest investments in the US, specifically the $10m (£6.4m) state- of-the-art commercial packaging facility in Audubon, Pennsylvania.
Almac, a provider of pharmaceutical development services to more than 600 companies in the pharmaceutical and biotech sectors across the world, is opening the 100,000 sq ft new facility in Audubon to service its customers across the US.
The new facility has already been awarded contracts for two products that will exceed 1.5m bottles per annum. Tablets and capsules will be manufactured in Almac’s Craigavon facility and shipped to Audubon for commercial packing into bottles for distribution to the US market. State of the art packaging lines will enable Almac to process blisters, bottles, wallets and sterile packaged product for the US market.
Gregory S Burton, who has recently taken up the post at the US Consulate in Belfast, took a tour of the Craigavon site and was briefed on the latest investments in the US, a market that represents around half of the Company’s total biotech and pharmaceuticals business.
“Almac’s most recent investment in the U.S. underscores Northern Ireland’s capacity to contribute to the global economy in high–value sectors like pharmaceutical development. The company plays an important role in my home State of Pennsylvania and I was grateful for the opportunity of viewing their cutting-edge facility in Craigavon.” commented Gregory S Burton
Further to the Audubon investment Almac is also in the process of doubling the size of its Analytical labs in its new North American Headquarters in Souderton, Pennsylvania, which was opened last year by Senator George Mitchell.
Graeme McBurney, Managing Director of Almac Pharma Services, said: “It gives me immense pride to know Almac is a source of direct foreign investment into the US at a time of restricted economic capital. We are investing in the business significantly across the globe so that we can continue to make an improving economic contribution both within our industry and major markets.”
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,300 and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
For media enquiries, please contact Tristan Jervis or Alex Heeley, De Facto Communications on +44 (0) 207 861 3838 or e-mail: firstname.lastname@example.org